Evaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT)
Running, not enrolling · Phase 3
Conditions studied: Beta-Thalassemia, Thalassemia, Genetic Diseases, Inborn, Hematologic Diseases, Hemoglobinopathies
In brief
This is a single-dose, open-label study in pediatric participants with TDT. The study will evaluate the safety and efficacy of autologous CRISPR-Cas9 modified CD34+ human hematopoietic stem and progenitor cells (hHSPCs) (CTX001).
Key facts
- Study ID
- NCT05356195
- Run by
- Vertex Pharmaceuticals Incorporated
- People needed
- 16
- Starts
- 2022-05-03
- Expected to finish
- 2027-11-14
- Last updated by the study team
- 2026-07-01
Who can join
Age: 2 and older, up to 11. Sex: any. Healthy volunteers: not accepted.
Where it is running
- TriStar Medical Group Children's Specialists - Pediatric Oncology — Nashville, Tennessee, United States
- Hospital for Sick Children - Hematology — Toronto, Canada
- University Hospital Dusseldorf - Department of Pediatric Oncology, Hematology and Clinical Immunology — Düsseldorf, Germany
- IRCSS Ospedale Pediatrico Bambino Gesu - Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica — Rome, Italy
- Great Ormond Street Hospital for Children — London, United Kingdom
- St.Mary's Hospital - Children's Clinical Research Facility — London, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.